RxDoctor Payments Data

Preethi Murty, MD

Nephrology · Steubenville, OHNPI 1437109576

Payments from drug & device makers

$553in general payments, 2019–2025

Across 14 payments — averaging $39.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$306
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$105
  • Otsuka America Pharmaceutical, Inc.$33
  • Daiichi Sankyo Inc.$26
  • Novartis$17
  • Fresenius USA Marketing, Inc.$17
  • plus $50 from 4 others

What the payments were for

  • Food & beverage$55099%
  • Education$31%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$553 in reported general payments places this provider in the 30th percentile of 450 nephrology providers in Ohio.

See all nephrology providers in Ohio

Medicare billing

Part B allowed, 2024
$238,137
Medicare patients
375
Services billed
1,830

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide47$152,138
FarxigaDapagliflozin Propanediol22$20,496
Lanthanum Carbonate19$16,325
Sevelamer Carbonate52$5,173
Calcitriol194$2,635
Bumetanide71$2,066
Potassium Chloride144$2,012
Midodrine Hcl36$1,906
Hydralazine Hcl158$1,733
Potassium Citrate ErPotassium Citrate23$1,531
Nifedipine ErNifedipine73$1,242
Losartan Potassium153$1,096
Furosemide294$1,070
Calcium Acetate18$837
Carvedilol116$707

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$17$152,13847 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 450 nephrology providers in Ohio.

Other nephrology in Steubenville

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →